Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2024
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid LeukemiaAditya Tedjaseputra, Nigel Russell, Richard Dillon
Acta Haematologica|November 26, 2023
Optimal Post-Remission Consolidation Therapy in Patients with AMLCarlos Jimenez-Chillon, Richard Dillon, Nigel Russell
Hematology. American Society of Hematology. Education Program|December 7, 2019
Minimal residual disease and stem cell transplantation outcomesJacqueline Cloos, Gert J Ossenkoppele, Richard Dillon
Idcases|September 12, 2018
Non-malignant CSF lymphocytosis in a patient with acute lymphoblastic leukemiaThomas Lofaro, Aritra Saha, Kavita Raj, et al.
British Journal of Haematology|October 15, 2020
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)Richard Dillon, Nicola Potter, Sylvie Freeman, et al.
Cancers|June 29, 2018
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid LeukemiaFrancesco Buccisano, Richard Dillon, Sylvie D Freeman, et al.
British Journal of Haematology|November 20, 2021
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trialsRichard Dillon, Robert K Hills, Alan K Burnett, et al.
British Journal of Hospital Medicine (London, England : 2005)|September 6, 2022
Optimising care for UK patients with acute myeloid leukaemiaAntonio Pagliuca, Asim Khwaja, Richard Dillon, et al.
BMJ (Clinical Research Ed.)|July 4, 2008
Fatal reactivation of hepatitis B after chemotherapy for lymphomaRichard Dillon, Gideon M Hirschfield, Michael E D Allison, et al.
Journal of Blood Transfusion|October 4, 2013
Comparative efficacy of three forms of parenteral ironRichard Dillon, Ibrahim Momoh, Yvonne Francis, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2024
SOHO State of the Art Updates and Next Questions: Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid LeukemiaAditya Tedjaseputra, Nigel Russell, Richard Dillon
Acta Haematologica|November 26, 2023
Optimal Post-Remission Consolidation Therapy in Patients with AMLCarlos Jimenez-Chillon, Richard Dillon, Nigel Russell
Hematology. American Society of Hematology. Education Program|December 7, 2019
Minimal residual disease and stem cell transplantation outcomesJacqueline Cloos, Gert J Ossenkoppele, Richard Dillon
Idcases|September 12, 2018
Non-malignant CSF lymphocytosis in a patient with acute lymphoblastic leukemiaThomas Lofaro, Aritra Saha, Kavita Raj, et al.
British Journal of Haematology|October 15, 2020
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)Richard Dillon, Nicola Potter, Sylvie Freeman, et al.
Cancers|June 29, 2018
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid LeukemiaFrancesco Buccisano, Richard Dillon, Sylvie D Freeman, et al.
British Journal of Haematology|November 20, 2021
Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trialsRichard Dillon, Robert K Hills, Alan K Burnett, et al.
British Journal of Hospital Medicine (London, England : 2005)|September 6, 2022
Optimising care for UK patients with acute myeloid leukaemiaAntonio Pagliuca, Asim Khwaja, Richard Dillon, et al.
BMJ (Clinical Research Ed.)|July 4, 2008
Fatal reactivation of hepatitis B after chemotherapy for lymphomaRichard Dillon, Gideon M Hirschfield, Michael E D Allison, et al.
Journal of Blood Transfusion|October 4, 2013
Comparative efficacy of three forms of parenteral ironRichard Dillon, Ibrahim Momoh, Yvonne Francis, et al.
Pageof 11